JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.
about
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatinThe role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignanciesJAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?Low-Dose Irradiation Enhances Gene Targeting in Human Pluripotent Stem CellsSelf-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansionNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phaseCopy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignanciesHydroxycarbamide: a user's guide for chronic myeloproliferative disorders.A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenMyeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint responseA small molecule directly inhibits the p53 transactivation domain from binding to replication protein A.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsRadiation, inflammation, and immune responses in cancerMice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasmGenetic complexity of myeloproliferative neoplasms.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.Many roads lead to MPN.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesJAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.Therapy with JAK2 inhibitors for myeloproliferative neoplasms.Development of JAK2V617F-positive polycythemia vera after chemotherapy-induced remission of primary central nervous system diffuse large B cell non-Hodgkin's lymphoma: a case report and review of the literature.Inherited predisposition to myeloproliferative neoplasmsLow-fidelity compensatory backup alternative DNA repair pathways may unify current carcinogenesis theories.RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation.Prognosis of Primary Myelofibrosis in the Genomic EraTET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.Leukemic transformation in essential thrombocythemia.Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number.Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress.Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.
P2860
Q24318979-C420C13F-8B45-4362-840F-557773D4C039Q27008221-2B32C8D9-EBF3-4431-9B2B-56AE5A07FE12Q27012572-9085FE0B-F151-466C-927C-C5499A275115Q27301084-7599E09D-DF91-46D3-A80A-D15A5B3A6E5AQ27317353-BAD26269-95E3-4649-884D-8408368EB1D4Q27687464-F244E49B-1F1F-460C-B5D8-3B71A81BBC1CQ30010486-355020DE-BE75-4238-911E-F9299F4A298FQ33419399-AB19A51A-7945-4963-8337-9F0E0E9F8019Q33558154-DC8F04BB-BC44-4592-AE55-3B23B65DF96FQ33788643-D4F6D8B3-4B0A-4027-9226-9653715CF926Q34171747-7CF453F8-7325-4302-B0A0-EA50635382EDQ34189794-46F63C83-9AD2-4FF5-9035-216DC5AE998DQ34375134-611EDDAE-6D71-4C54-B661-C999F40DF9EBQ34409236-2A760810-2FA9-4CA1-BF27-AA873E308D55Q34522635-3E86723E-DB8C-45D0-8C6E-BFBDF72AAE38Q34640790-C9EFDB0C-4FEC-4BC5-9278-FF17490191F9Q34652224-ADC58E86-5D32-4129-808D-AFAD17BC2E5CQ34968444-B95D7805-FF68-4CAA-80DA-90B1B276670AQ35132280-2B2CE1D6-12BB-49DC-8946-02530C79F676Q36005646-6D466C18-600E-4C7B-8512-0600D35204D0Q36108482-F4AED648-95F6-4B2C-8C4B-4AA34A79950AQ37255024-A898E74A-862E-4F3A-8AE0-62D9902A3DB6Q37379320-E3EF18DD-CEBD-459E-845D-7B280430A426Q37460337-96EC0A35-A744-478F-B469-4105BB93B882Q37555785-1D5B9B0E-D0A6-4A62-82CD-011A9EABE48EQ37683806-45CF6559-2893-4983-9253-648D5A2B3519Q37687519-339754C8-0D4A-4FE4-A3E6-58C4C0D2618AQ37810100-A28FE46F-59E8-47BC-A408-92B892951260Q38046321-333CF662-10F2-4CD9-830C-05FE84A4E764Q38104894-13079909-7EAD-4B37-A0F1-E561DF74902FQ38127417-0AC9C108-2BAE-4FF1-963E-CF896A5BFA69Q38221690-082F408C-841D-4BEC-8E27-077D7271C847Q38810353-52FF7B6E-202D-4F90-AE33-45E1B9D73D7EQ38847266-07F88387-0D07-4E5C-A5BA-B9DBA7D46D6BQ38926804-ED422A51-5133-4EE4-A17B-FF6CCF2C1782Q39005258-A318DF8E-2B06-467B-A798-029097370EC3Q39069487-6DCA21BF-FA01-440A-AABE-7928CE9FE699Q39308537-5CB78E41-2CF2-4EF3-AA66-C327C9F2AA6CQ39346123-B05BFE20-7025-4001-92CF-DACE89C3D3BFQ39545218-581938EF-5069-42F9-B595-2A96CE9F6730
P2860
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
JAK2 stimulates homologous rec ...... myeloproliferative disorders.
@en
JAK2 stimulates homologous rec ...... myeloproliferative disorders.
@nl
type
label
JAK2 stimulates homologous rec ...... myeloproliferative disorders.
@en
JAK2 stimulates homologous rec ...... myeloproliferative disorders.
@nl
prefLabel
JAK2 stimulates homologous rec ...... myeloproliferative disorders.
@en
JAK2 stimulates homologous rec ...... myeloproliferative disorders.
@nl
P2093
P50
P1433
P1476
JAK2 stimulates homologous rec ...... f myeloproliferative disorders
@en
P2093
Lisa Wiesmuller
Mayuka Nakatake
Stéphane Giraudier
P304
P356
10.1182/BLOOD-2008-01-134114
P407
P577
2008-05-30T00:00:00Z